TASL-TSOC Taiwan Position Statement for the Management of Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Diseases.

Metabolic dysfunction associated fatty liver disease (MAFLD) is an increasingly important and common liver disease worldwide. The diagnosis of MAFLD is based on the presence of steatosis on image/histology/serum markers accompanied with presence of at least one of the three metabolic features that include overweight/obesity, type II diabetes mellitus, and metabolic risk factors. MAFLD is not only a liver disease but also a contributing or related factor of cardiovascular diseases (CVD) which lead to the major etiology of morbidity and mortality in patients with MAFLD. Hence, understanding the association of MAFLD and CVD, surveillance and risk stratification of MAFLD in patients with CVD, and current status of management of MAFLD are urgently needed for both hepatologist and cardiologist. The purpose of this Taiwan position statement is to review literature and provide suggestions that cover from epidemiology, etiology, risk factors, risk stratification, non-pharmacological intervention, and potential drug treatment of MAFLD, especially focusing on association with CVD.